FBC
SRPT icon

Fairfield, Bush & Co’s Sarepta Therapeutics SRPT Stock Holding History

Fairfield, Bush & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40
Closed -$4.58K – 447
2023
Q2 		$4.58K Buy
+40
New +$5.16K ﹤0.01% 376
2022
Q3 		– Sell
-40
Closed -$3K – 413
2022
Q2 		$3K Buy
+40
New +$2.94K ﹤0.01% 382

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fairfield, Bush & Co's SRPT Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 40 shares — an estimated $4.58K sold.

Fairfield, Bush & Co first reported a position in SRPT in Q2 2022 and held it in 2 quarters. The position peaked at $4.58K in Q2 2023. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

  • Fairfield, Bush & Co reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Fairfield, Bush & Co sold 40 Sarepta Therapeutics shares in Q3 2023, an estimated $4.58K.
  • Fairfield, Bush & Co first reported a position in Sarepta Therapeutics in Q2 2022 and held it in 2 quarters.
  • Fairfield, Bush & Co's Sarepta Therapeutics position peaked at $4.58K in Q2 2023.
  • 394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.